Literature DB >> 2553608

Pentoxifylline modulation of plasma membrane functions in human polymorphonuclear leukocytes.

W L Hand1, M L Butera, N L King-Thompson, D L Hand.   

Abstract

Pentoxifylline is known to have major effects on cell membrane function in mammalian cells, including human leukocytes. The protective effects of this agent in animal models of infection and inflammation may be due to alterations in phagocyte (neutrophil and macrophage) function. However, the exact mechanism of action of pentoxifylline is unknown. In this study, we evaluated the effect of the drug on several membrane-associated activities in human polymorphonuclear neutrophils and investigated possible mechanisms for the observed changes in neutrophil function. Pentoxifylline inhibited ingestion of microbial particles (Staphylococcus aureus and zymosan); decreased superoxide generation activated by zymosan, formyl-methionyl-leucyl-phenylalanine, and concanavalin A (but not phorbol myristate acetate); and decreased uptake (transport) of adenosine stimulated by formyl-methionyl-leucyl-phenylalanine and zymosan. In contrast, pentoxifylline actually increased clindamycin uptake in zymosan-stimulated polymorphonuclear neutrophils. However, pentoxifylline had no effect on uptake of adenosine or clindamycin in unstimulated neutrophils. In comparison with known inhibitors of nucleoside transport (nitrobenzylthioinosine and dipyridamole), the results suggested that pentoxifylline does not bind to membrane nucleoside transport receptors. At concentrations which inhibit neutrophil function, pentoxifylline activity is not mediated through external membrane nucleoside regulatory sites. Thus, pentoxifylline affects the activation signal chain at a point beyond the membrane receptors. Whatever its precise mechanism of action, pentoxifylline has a striking modulatory effect on cell membrane-associated responses in stimulated leukocytes and may prove useful for control of injurious inflammatory states.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2553608      PMCID: PMC259862          DOI: 10.1128/iai.57.11.3520-3526.1989

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  42 in total

1.  Effect of pentoxifylline on the phagocytic activity, cAMP levels, and superoxide anion production by monocytes and polymorphonuclear cells.

Authors:  H Bessler; R Gilgal; M Djaldetti; I Zahavi
Journal:  J Leukoc Biol       Date:  1986-12       Impact factor: 4.962

2.  Pentoxifylline and intermittent claudication.

Authors:  J A Spittel
Journal:  Ann Intern Med       Date:  1985-01       Impact factor: 25.391

Review 3.  Clinical implications of guanine nucleotide-binding proteins as receptor-effector couplers.

Authors:  A M Spiegel; P Gierschik; M A Levine; R W Downs
Journal:  N Engl J Med       Date:  1985-01-03       Impact factor: 91.245

4.  Enhancement of chemotaxis and protection of mice from infection.

Authors:  G W Sullivan; T N Patselas; J A Redick; G L Mandell
Journal:  Trans Assoc Am Physicians       Date:  1984

5.  Adenosine as a bronchoconstrictor mediator in asthma and its antagonism by methylxanthines.

Authors:  S T Holgate; J S Mann; M J Cushley
Journal:  J Allergy Clin Immunol       Date:  1984-09       Impact factor: 10.793

6.  Identification of distinct activation pathways of the human neutrophil NADPH-oxidase.

Authors:  I Maridonneau-Parini; S M Tringale; A I Tauber
Journal:  J Immunol       Date:  1986-11-01       Impact factor: 5.422

7.  Adenosine; a physiologic modulator of superoxide anion generation by human neutrophils. Adenosine acts via an A2 receptor on human neutrophils.

Authors:  B N Cronstein; E D Rosenstein; S B Kramer; G Weissmann; R Hirschhorn
Journal:  J Immunol       Date:  1985-08       Impact factor: 5.422

8.  Contrasts between phagocyte antibiotic uptake and subsequent intracellular bactericidal activity.

Authors:  W L Hand; N L King-Thompson
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

9.  Filterability of subpopulations of leukocytes: effect of pentoxifylline.

Authors:  E A Schmalzer; S Chien
Journal:  Blood       Date:  1984-08       Impact factor: 22.113

10.  Pentoxifylline in the treatment of experimental peritonitis in rats.

Authors:  G E Chalkiadakis; A Kostakis; P E Karayannacos; M E Chalkiadakis; S Sgouromali; H Giamarellou; G D Skalkeas
Journal:  Arch Surg       Date:  1985-10
View more
  5 in total

1.  Alteration of the functional effects of granulocyte-macrophage colony-stimulating factor on polymorphonuclear leukocytes by membrane-fluidizing agents.

Authors:  E S Buescher; S M McIlheran; S M Banks; S Vadhan-Raj
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

2.  Effects of pentoxifylline on equine neutrophil function and flow properties.

Authors:  D J Weiss; R J Geor; S M Burris; C M Smith
Journal:  Can J Vet Res       Date:  1992-10       Impact factor: 1.310

3.  Effect of pentoxifylline on decreased in vitro mononuclear leucocyte chemotaxis in vascular and polysystemic autoimmune diseases.

Authors:  Z Szekanecz; G Szabó; I Sonkoly; Z Bedö; G Szegedi
Journal:  Agents Actions       Date:  1991-07

4.  Pentoxifylline modulates activation of human neutrophils by amphotericin B in vitro.

Authors:  G W Sullivan; H T Carper; G L Mandell
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

5.  Influence of pentoxifylline and its derivatives on antibiotic uptake and superoxide generation by human phagocytic cells.

Authors:  W L Hand; D L Hand
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.